BOSTON, LAUSANNE, Switzerland, and HIROSHIMA, Japan, Feb.
22, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
today announced an agreement with Hiroshima University, one of the top public
universities in Hiroshima City,
Japan, to support their molecular
profiling by next-generation sequencing (NGS) in investigating the
pathogenic variants causing different blood cancer disorders.
Hiroshima University is home to
one of the largest university research institutes in the field of
radiation biomedical science in Japan. With NGS for myeloid
testing not widely available in Japan, a group of Hiroshima University researchers tapped the
SOPHiA DDM Platform to assist with the clinical utility of NGS
tests for myeloid malignancies. Hiroshima University aimed to establish a
framework where the NGS-based testing would become a routine part
of clinical diagnosis for myeloid neoplasms.
Following the adoption of the SOPHiA DDM Platform, Masatoshi Nishizawa from Hiroshima University presented a research case
study at the 83rd Annual Meeting of Japanese Society of
Hematology (Sendai, September 23-25,
2021). Leveraging the SOPHiA DDM Platform's unique
algorithmic capabilities, the researchers from Hiroshima University detailed their
experience with the first 24 samples of myeloid solution collected
and analyzed as part of a research project to evaluate the clinical
utility of NGS testing for myeloid malignancies. The evaluation
showed that the SOPHiA DDM platform's unique capabilities in
support of NGS testing were both useful and feasible in identifying
druggable targets and making precise diagnosis and prognosis to
help benefit more patients in Japan. The work of Hiroshima University has since been shared
with Japanese laboratories and clinicians, and the university aims
to continue its evaluation with additional samples over the next 12
months.
"SOPHiA GENETICS is committed to improving patient outcomes
through the practice of data driven medicine. We work with several
oncohematology centers around the world and are now eager to start
supporting the Japanese oncohematology network of hospitals. The
more data we compute, the more benefit we bring to all our users to
ultimately accelerate the democratization of data-driven-medicine,"
said Jurgi Camblong, co-founder and CEO of SOPHiA GENETICS.
"To make a personalized treatment in the real-world practice of
oncohematology prevail, the sophistication of diagnostic gene
panels is strongly desired," said Tatsuo
Ichinohe, Director of the Department of Hematology and
Oncology at Hiroshima University Hospital. "SOPHiA GENETICS'
Myeloid Plus Solution is one of the best examples I have ever seen
in terms of its ease of use and wide coverage."
SOPHiA GENETICS' partnership with Hiroshima University follows the company's
March 2021 announcement of a
long-term collaboration agreement with Hitachi, Ltd. To bring
clinical, genomic, and real-world insights to more Japanese
healthcare providers and pharmaceutical and biopharmaceutical
companies. In partnership with Hitachi, discussions continue with
additional Japanese institutions who may also benefit from SOPHiA
GENETICS for oncohematological cancer research.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a healthcare technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
780 hospital, laboratory, and biopharma institutions globally. For
more information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenertics.com to obtain
the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this press release speak only as of the
date hereof . We expressly disclaim any obligation or undertaking
to update these forward-looking statements contained in this press
release to reflect any change in our expectations or any change in
events, conditions, or circumstances on which such statements are
based, unless required to do so by applicable law. No
representations or warranties (expressed or implied) are made about
the accuracy of any such forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg